Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quart... ( Quarterly Reports Use Market Intellig...)

Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008

Date:1/21/2009

Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry

PHILADELPHIA and LONDON, Jan. 21 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July - September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:

    DRUG          DISEASE                     COMPANY

    Zeftera(TM)   Complicated skin and soft   Basilea Pharmaceutica
                  tissue infections

    Firazyr(R)    Hereditary angioedema       Jerini

    Bridion(R)    Reversal of muscle          Schering-Plough
                  relaxants

    Cleviprex(TM) Perioperative               The Medicines Company
                  hypertension

    Xarelto(R)    Venous thromboembolic       Bayer/Ortho-McNeil
                  events                      Pharmaceutical

More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.p
'/>"/>

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
10. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
11. Thomson Healthcare Launches Application That Assesses Physician Performance

Post Your Comments:

(Date:11/30/2009)... , The European Association of Urology (EAU) and ...he fight against prostate cancer, have entered int...-term commitment to increase and improve,patient ...eases., Professor Per-Anders Abrahamsson, Secret...U affiliated partnership, Europa Uomo will gain ac...

(Date:11/30/2009)... CHICAGONovember 30, 2009A pet owner knows the en... especially in troubled times. Most pets are consi...eable companions. A growing body of research now d...ld development, elderly care, mental illness, phys...ry, and the rehabilitation of incarcerated youth a...

(Date:11/30/2009)... The University of Navarra Hospital has launched ... efficacy of an immunotherapy treatment. This appr...ines produced from healthy and tumour cells from t...lioblastomas, one of the most aggressive and frequ...ered to participating patients combined with the s...

(Date:11/30/2009)... Author of "My Two-Y...r raising children who love to eat everything. , ...-- Do you have a picky eater in your house? Do yo...altime? Three new short online videos – one...ners, and the third on answers for real-life paren...

(Date:11/30/2009)...Like a pothole that worsens over time, so do knees...ONDAY, Nov. 30 (HealthDay News) -- If you,re a mid...tball court or hockey rink, take note: A new study...ost the risk of internal knee damage that could le...e injuries occurred in middle-age people who showe...

Breaking Medicine News(10 mins):Health News:The therapeutic benefits of the human-animal bond 2 Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2 Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3 Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4 Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5 Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6 Health News:New Videos Help Parents of Picky Eaters 2 Health News:New Videos Help Parents of Picky Eaters 3 Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2 Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3

[0] Affiliate partnership between EAU and Europa Uomo [0] The therapeutic benefits of the human-animal bond [0] Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines [0] New Videos Help Parents of Picky Eaters [0] Lots of Exercise in Midlife May Lead to Osteoarthritis

...mirror LLC, a Philadelphia-based company offering ...DNA testing, is announcing the launch of their inn... affordable, easy-to-use product, with its user-fr...l HIV disease progression. HIVmirror(TM) i...

...earth endures, seedtime and harvest, cold and heat...e." - (Genesis 8:22, The Bible ). ...metime now. Needless to say, we, the people, of th...g the environmental crisis began way back in the t...

...enter for Consumer Freedom (CCF) welcomed a new st...tric & Adolescent Medicine, which will contribute ... the supposed link between television food adverti...that "children do not currently see more food ads ...

...udies have already revealed that stress boosts the...ers disease, a new study on mice has now shown th...ress-induced increases. The study, reported...first studies to elaborate the basic biomolecular ...

...ted wheat germ extract inhibits estrogen positive ...than the world's best selling cancer drug, Tamoxi...kend at the 2007 meeting of the American Society o...cal trials. In the current study, Andras Telekes, ...

...ound that tumor cell activity in women differs acc...east cancer in younger women. Breast canc... to treatment in women under 50 as compared to old...searchers led by Carey Anders at the Duke Institut...

Other Medicine News:Health News:HIVmirror, LLC Launching Breakthrough Genetic Product for HIV Positive Consumer 2 Health News:World Environment Day (International Polar Year) 2 Health News:World Environment Day (International Polar Year) 3 Health News:World Environment Day (International Polar Year) 4 Health News:New Studies: Commercials Aren't Making Kids Fat 2 Health News:Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice 2 Health News:Wheat Germ Extract Inhibits Breast Cancer in Study 2

HIVmirror, LLC Launching Breakthrough Genetic Product for HIV Positive Consumer World Environment Day (International Polar Year)New Studies: Commercials Aren't Making Kids Fat Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice Wheat Germ Extract Inhibits Breast Cancer in Study Breast Cancer More Aggressive and Less Responsive to Treatment in Younger Women

(Date:11/30/2009)... , , INDIANAPOLIS, Nov. 30 /PRNew...tration (FDA) has approved Cymbalta® (duloxet...zed anxiety disorder (GAD) in adults, Eli Lilly an...ince generalized anxiety disorder can be a chronic...atients find a treatment option that is effective ...

(Date:11/30/2009)... , , THOUSAND OAKS, Calif., Nov. 30 /PR... today announced that it will present updated long...omiplostim) in adult chronic immune (idiopathic) t... will present the first Nplate study in a pediatri...tic syndromes (MDS) at the 2009 American Society o...

(Date:11/29/2009)... , , CHICAGO, Nov. 30 Rad...is from a remote location with the use of a handhe...ftware, according to a study presented today at th...rth America (RSNA). ,, "The goal is to improve...ell as to improve communications among different c...

Breaking Medicine Technology:FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2 FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3 FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4 FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5 Amgen Highlights Data to be Presented at ASH 2 Amgen Highlights Data to be Presented at ASH 3 Amgen Highlights Data to be Presented at ASH 4 Amgen Highlights Data to be Presented at ASH 5 Amgen Highlights Data to be Presented at ASH 6 Amgen Highlights Data to be Presented at ASH 7 Amgen Highlights Data to be Presented at ASH 8 Amgen Highlights Data to be Presented at ASH 9 Amgen Highlights Data to be Presented at ASH 10 Amgen Highlights Data to be Presented at ASH 11 Smart Phones Allow Quick Diagnosis of Acute Appendicitis 2 Smart Phones Allow Quick Diagnosis of Acute Appendicitis 3 LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 1 LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 2 LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 3 LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 4 SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 1 SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 2 SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 3 SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 4 SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 5 PDL BioPharma Elects Barry Selick to Its Board of Directors 53479 1 PDL BioPharma Elects Barry Selick to Its Board of Directors 53479 2

[0] FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder [0] Amgen Highlights Data to be Presented at ASH [0] Smart Phones Allow Quick Diagnosis of Acute Appendicitis

..., Fla. , May 29 GlaxoSmithKline [NYSE: GSK] and ...ted States Food and Drug Administration,s (FDA) On...o three that the ARZERRA(TM) (ofatumumab) data are... patients with chronic lymphocytic leukemia (CLL) ...mtuzumab. Ofatumumab is an investigational treatme...

...VILLE, Pa., May 29 Wyeth Pharmaceuticals, a divis...minary data from two ongoing studies, one evaluati...umab (Herceptin(R), Roche) in HER-2 positive (ErbB...nvestigating neratinib safety and efficacy when gi...b) in patients with HER-2 dependent solid tumors. ...

Other Medicine Technology:FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2 FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3 FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4 FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5 New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 2 New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 3 New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 4 New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 5

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

7121B Sony Medical Monitor

...ompletely new and revolutionary lens system. The u... size without distortion. The 115 field of view su...tion of the telescope. Beyond that a new quick loc... is introduced. It is the combination of outstandi...

...e the surgeon with an optimal work area and reduce...t and retinal surgery. Perfect Pupil Injectable is...pils which allows expansion of the pupil to 8mm co...gery, and allows the pupil to return to its normal...

Defiant 95% Bag Filter

Medicine Products:

7121B Sony Medical Monitor Olympus TrueView II Perfect Pupil Injectable Defiant 95% Bag Filter

Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quart...( Quarterly Reports Use Market Intellig...),Health